MetaVia Inc. — Director's Dealing 2016

Aug 12, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Gemphire Therapeutics Inc. (GEMP)
CIK: 0001638287
Period of Report: 2016-08-10

Reporting Person: SASSINE ANDY (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-08-10	Common Stock	C	75080	—	Acquired	75080	Direct
2016-08-10	Common Stock	J	8212	$6.7059	Acquired	83292	Direct
2016-08-10	Common Stock	C	31853	$6.7059	Acquired	115145	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-08-10	Series A Convertible Preferred Stock	$	C	75080	Disposed		Common Stock (75080)	Direct
2016-08-10	8% Convertible Subordinated Promissory Notes	$6.7059	C		Disposed		Common Stock (31853)	Direct

Footnotes

F1: The Series A Convertible Preferred Stock converted into shares of common stock, par value $0.001 per share (the "Common Stock"), of Gemphire Therapeutics Inc. (the "Company") on a one-for-one basis immediately prior to the closing of the Company's initial public offering and had no expiration date.

F2: Represents shares of Common Stock issued for payment of accrued dividends on the Series A Convertible Preferred Stock.

F3: The notes were issued in the original principal amount of $200,000. The outstanding principal and $13,611 of accrued interest on the notes automatically converted into shares of Common Stock immediately prior to the closing of the Company's initial public offering.